Novartis Ag (NVS) FCF Payout Ratio Growth (3y) (2012 - 2026)
Powered by 
Analysis
Novartis Ag (NVS) FCF Payout Ratio Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | -24.09% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 32.12% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -11.39% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -17.24% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 12.77% |
| Mar 31, 2025 | 29.71% |
| Mar 31, 2024 | 12.33% |
| Mar 31, 2023 | 2.79% |
| Mar 31, 2022 | -16.88% |
| Mar 31, 2021 | -7.26% |
| Mar 31, 2020 | 2.41% |
| Dec 31, 2019 | -14.89% |
| Mar 31, 2019 | 9.79% |
| Mar 31, 2018 | 6.32% |
| Mar 31, 2017 | 10.05% |
| Dec 31, 2016 | -15.48% |
| Mar 31, 2016 | -8.56% |
| Dec 31, 2015 | 24.32% |
| Mar 31, 2015 | -14.20% |
| Dec 31, 2014 | 19.94% |
| Mar 31, 2014 | -17.53% |
| Dec 31, 2013 | 12.80% |
| Jun 30, 2013 | 32.96% |
| Mar 31, 2013 | -28.51% |